Novo Nordisk obesity pill results send shares to record high

Novo Nordisk (NYSE:NVO) unveiled a potential game changer during its Capital Markets Day with data on experimental obesity pill amycredtin potentially outperforming its blockbuster drug Wegovy. An early-stage test conducted over 12 weeks showed patients taking the pill lost 13% of their weight. Though trials are still in their early stages, Novo Nordisk (NYSE:NVO) hopes it can add another killer app to its portfolio of weight-loss drugs. The successes of Wegovy and Novo Nordisk’s other injection-based obesi ...